US FDA approves Elanco's treatment for parasitic infections in dogs (updated)

Elanco Animal Health Incorporated

07/10/2024 23:43

(Adds CEO comment in paragraph 5, background in paragraphs 6,7)
    By Mariam Sunny
       Oct 7 (Reuters) - The U.S. Food and Drug Administration
has approved Elanco Animal Health's  ELAN.N  oral drug to
protect dogs against six parasitic infections, the company said
on Monday.
    The drug, branded as Credelio Quattro, is a single, monthly
chewable tablet for dogs eight weeks of age or older, the
company said.  
    The drug is approved for the treatment of flea and tick
infestations, along with roundworm, hookworm and tapeworm
infections. It is also approved to prevent flea infestations and
 heartworm disease in dogs.
    The company expects to launch the drug in the first quarter
of 2025. 
    "We see this innovation will expand the market ... and we
will price it according to that value proposition," CEO Jeff
Simmons told Reuters in an interview.
    Elanco expects Credelio Quattro to become one of its
potential blockbusters, along with the recently launched
Zenrelia, its first product in the market related to skin
disease treatments for dogs.
        The currently available paraciticide treatments for dogs
include Boehringer Ingelheim's Nexgard Plus and Zoetis'  ZTS.N 
Simparica Trio, which offer protection against fleas, ticks,
heartworm disease, roundworms and hookworms.   

 (Reporting by Mariam Sunny in Bengaluru; Editing by Devika
Syamnath)
 ((Mariam.ESunny@thomsonreuters.com))